hel-2

WP1066 是一种新型JAK2和STAT3抑制剂，对 STAT5 和 ERK1 2 也起作用。它用于研究黑色素瘤、脑癌、实体瘤和中枢神经系统肿瘤治疗。

AB25583是一种小分子Polθ 解旋酶 (Polθ-hel) 抑制剂，具有6 nM 的IC50值。该化合物能选择性地消灭BRCA1 2缺陷细胞，且能与Olaparib在携带BRCA1 2致病性突变的癌症细胞中发挥协同效应。AB25583主要应用于肿瘤相关的研究领域。

Lornoxicam-d4 is intended for use as an internal standard for the quantification of lornoxicam by GC- or LC-MS. Lornoxicam is a COX inhibitor and non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory and analgesic properties. It inhibits production of thromboxane B2 from arachidonic acid in HEL human erythroleukemic cells, which endogenously express COX-1, as well as inhibits LPS-induced formation of prostaglandin F1α from arachidonic acid in Mono-Mac-6 cells, which endogenously express COX-2. Lornoxicam reduces LPS-induced production of nitric oxide and IL-6 in cell-based assays with IC50 values of 65 and 54 µM, respectively. It reduces carrageenan-induced paw edema in rats when administered intravenously at doses ranging from 0.1 to 9 mg kg. Formulations containing lornoxicam have been used in the management of postoperative pain.